Incidence of Preexisting B-cell Aplasia in B-ALL: Implications for Post-CAR T-cell Monitoring

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Oct 25

PMID 39454282

Authors

Isha Sahai

Paul Borgman

Bonnie Yates

Sergio Rosenzweig

Shakuntala Rampertaap

Alexander W Rankin

Nirali N Shah

Affiliations

Soon will be listed here.

References

Pulsipher M, Han X, Maude S, Laetsch T, Qayed M, Rives S . Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discov. 2022; 3(1):66-81. PMC: 9924295. DOI: 10.1158/2643-3230.BCD-21-0095. View

Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E . Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy. Blood Adv. 2023; 8(8):1959-1963. PMC: 11021820. DOI: 10.1182/bloodadvances.2023011168. View

Leitenberg D, Rappeport J, Smith B . B-cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol. 1994; 102(2):231-6. DOI: 10.1093/ajcp/102.2.231. View

Brudno J, Kochenderfer J . Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024; 21(7):501-521. PMC: 11529341. DOI: 10.1038/s41571-024-00903-0. View

Schatorje E, Gemen E, Driessen G, Leuvenink J, van Hout R, de Vries E . Paediatric reference values for the peripheral T cell compartment. Scand J Immunol. 2012; 75(4):436-44. DOI: 10.1111/j.1365-3083.2012.02671.x. View

Antikainen E, Gronroos M, Huurre A, Korhonen L, Peltola V, Lahteenmaki P . Treatment intensity affects immune reconstitution even after childhood cancer not treated with hematopoietic stem cell transplantation. Cancer Rep (Hoboken). 2024; 7(5):e2069. PMC: 11104287. DOI: 10.1002/cnr2.2069. View

Lamble A, Myers R, Taraseviciute A, John S, Yates B, Steinberg S . Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2022; 7(4):575-585. PMC: 9979750. DOI: 10.1182/bloodadvances.2022007423. View

OBrien M, Ji L, Shah N, Rheingold S, Bhojwani D, Yuan C . Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022; 40(9):956-967. PMC: 8937013. DOI: 10.1200/JCO.21.01693. View

Avanzini M, Locatelli F, Santos C, Maccario R, Lenta E, Oliveri M . B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp Hematol. 2005; 33(4):480-6. DOI: 10.1016/j.exphem.2005.01.005. View

10.

Hill J, Seo S . How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020; 136(8):925-935. PMC: 7441168. DOI: 10.1182/blood.2019004000. View

11.

Molinos-Quintana A, Alonso-Saladrigues A, Herrero B, Caballero-Velazquez T, Galan-Gomez V, Panesso M . Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role.... Front Immunol. 2024; 14:1280580. PMC: 10825008. DOI: 10.3389/fimmu.2023.1280580. View

12.

Finney O, Brakke H, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M . CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019; 129(5):2123-2132. PMC: 6486329. DOI: 10.1172/JCI125423. View

13.

Qayed M, Bleakley M, Shah N . Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia. Curr Opin Hematol. 2021; 28(6):373-379. PMC: 9079121. DOI: 10.1097/MOH.0000000000000685. View

14.

Bommier C, Maurer M, Lambert J . What clinicians should know about surrogate end points in hematologic malignancies. Blood. 2024; 144(1):11-20. DOI: 10.1182/blood.2023022269. View